Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629703
Status:
COMPLETED
Last Update Posted:
2023-08-18
First Post:
2020-11-13
Brief Title:
Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor:
Rigel Pharmaceuticals
Organization:
Rigel Pharmaceuticals
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-05
Completion Date Type:
ACTUAL
First Submit Date:
2020-11-13
First Submit QC Date:
November 13 2020
Study First Post Date:
2020-11-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2023-08-15
Disp First Submit QC Date:
August 15 2023
Disp First Post Date:
2023-08-18
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-08-15
Last Update Post Date:
2023-08-18
Last Update Post Date Type:
ACTUAL